Skip to main content

Table 2 Prophylactic treatment, angioedema attack frequency and necessity for acute attack treatment at baseline and follow-up

From: High occurrence of antihistamine resistance in patients with recurrent idiopathic angioedema

  Baseline (n = 120) Follow-up (n = 120)
Prophylactic treatment (%)
 Unknown 3 (3%) 0 (0%)
 None 62 (52%) 18 (15%)
 Antihistamine mono-therapy 45 (38%) 87 (73%)
  Onefold daily dose 27 (23%) 17 (14%)
  Twofold daily dose 11 (9%) 30 (25%)
  Threefold daily dose 2 (2%) 7 (6%)
  Fourfold daily dose 5 (4%) 21 (18%)
  > Fourfold daily dose 0 (0%) 12 (10%)
 Antihistamines + add-on 7 (6%)a 15 (13%)c
 Other treatment 3 (3%)b 0 (0%)
  Baseline (n = 120) All n = 120 No intervention n = 21d Antihistamines only n = 99 + Add-on n = 99
Attack frequency (%)
 Unknown 17 (14%) 15 (13%) 3 (14%) 11 (11%) 12 (12%)
 ≥ 1 per week 42 (35%) 15 (13%) 2 (10%) 17 (17%) 13 (13%)
 ≥ 1 per month 44 (37%) 24 (20%) 4 (19%) 23 (23%) 20 (20%)
 ≥ 1 per year 17 (14%) 30 (25%) 6 (29%) 23 (23%) 24 (24%)
 No attack 0 (0%) 36 (30%) 6 (29%) 25 (25%) 30 (30%)
  Baseline (n = 120) All = 120 No intervention n = 21 Antihistamines + add-on n = 99
Acute attack treatment (%)e
 Unknown 15 (13%) 18 (15%) 3 (14%) 15 (15%)
 None 11 (9%) 51 (43%) 6 (29%) 45 (45%)
 1. Antihistamines 25 (21%) 26 (22%) 8 (38%) 18 (18%)
 2. Antihistamines and/or corticosteroids 14 (12%) 17 (14%) 2 (10%) 16 (16%)
 3. Epipen 5 (4%) 3 (3%) 1 (5%) 2 (2%)
 4. Urgent care center 43 (36%) 5 (4%) 2 (10%) 3 (3%)
 5. Hospitalization or Intensive care 7 (6%) 0 (0%) 0 (0%) 0 (0%)
  1. aAntihistamines combined with leukotriene antagonist (n = 2), corticosteroids (n = 3), H2 antagonist (n = 1), tranexamic acid (n = 1)
  2. bMonotherapy with tranexamic acid (n = 2) or H2 antagonist (n = 1)
  3. cAntihistamines combined with omalizumab (n = 8), omalizumab and tranexamic acid (n = 1), leukotriene antagonist (n = 1), cyclosporine (n = 1), tranexamic acid (n = 2), sulfalazine (n = 1), H2 antagonist (n = 1)
  4. dNo prophylaxis (n = 18) no antihistamine dose increase (n = 3)
  5. eOverview of the most invasive reported symptomatic treatment used by patients during an acute attack including the reported need for medical care where invasiveness was reported from 1 to 5